¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð - À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Aerosol Drug Delivery Devices Market Size Study, By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, and Regional Forecasts 2022-2032
»óǰÄÚµå : 1681304
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,181,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,068,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 263¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù.

ÀÌ ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö 13.16%ÀÇ ³î¶ó¿î CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÷´Ü ÈíÀԱ⠱â¼ú äÅÃ, ÇコÄɾ ´ëÇÑ ÀÎ½Ä Áõ°¡ÀÔ´Ï´Ù. ÀçÅà ġ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ÈíÀÔ±â¿Í ºÐ¹«±â´Â õ½Ä, COPD, ³¶Æ÷¼º ¼¶À¯Áõ°ú °°Àº ¸¸¼º È£Èí±â ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸® ÀâÀ¸¸é¼­ ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ¹Ì±¹ ÆóÇùȸ¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â 1,170¸¸ ¸í ÀÌ»óÀÇ ¼ºÀÎÀÌ COPD Áø´ÜÀ» ¹Þ¾Ò½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â 2030³â±îÁö Àü ¼¼°è »ç¸ÁÀÚ 5¸í Áß 1¸íÀÌ È£Èí±â ÁúȯÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Åë°è´Â ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â°¡ Áúº´ °ü¸®¸¦ À§ÇÑ Áß¿äÇÑ ¼Ö·ç¼ÇÀÓÀ» °­Á¶ÇÕ´Ï´Ù. ¶ÇÇÑ, ÇコÄɾ ´ëÇÑ Á¢±Ù¼º°ú ±â¼ú Çõ½Å¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÈíÀÔ±â ÀåÄ¡, ƯÈ÷ »ç¿ë·® ÃßÀû ¹× ¼øÀÀµµ Çâ»óÀ» À§ÇÑ ¼¾¼­¸¦ Æ÷ÇÔÇÑ ÀåÄ¡ÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ȯÀÚ°¡ Áúº´À» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÏ°í º¸´Ù Á¤È®ÇÑ ¾à¹°Àü´ÞÀ» º¸ÀåÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î, ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ Áö¼ÓÀûÀ¸·Î Çâ»óµÊ¿¡ µû¶ó ȯÀÚµéÀº º¸´Ù È¿°úÀûÀ¸·Î Áúº´À» °ü¸®Çϱâ À§ÇØ ÈíÀÔ±â¿Í ºÐ¹«±â¸¦ ¼±ÅÃÇÏ°Ô µÇ¾ú½À´Ï´Ù.

Äڷγª19 ÆÒµ¥¹ÍÀº Äڷγª19¿Í °°Àº È£Èí±â Áúȯ°ú ±× ÇÕº´ÁõÀ¸·Î ÀÎÇØ È£Èí±â Áö¿øÀÇ Çʿ伺ÀÌ ³ô¾ÆÁ³±â ¶§¹®¿¡ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå¿¡ ÀÌÁßÀ¸·Î ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹ÍÀº ¶ÇÇÑ ¼¼°è °ø±Þ¸Á¿¡ È¥¶õÀ» ÀÏÀ¸ÄÑ ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ »ý»ê¿¡ ÀϽÃÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí, ÀçÅÃÄ¡·á ¼­ºñ½º Áõ°¡¿Í ½º¸¶Æ® ÈíÀÔ ÀåÄ¡ÀÇ Ã¤ÅÃÀ¸·Î ½ÃÀåÀº ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå¿¡¼­ ºÏ¹Ì´Â 2024³â Àüü ¸ÅÃâÀÇ 39% ÀÌ»óÀ» Â÷ÁöÇÏ¸ç °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À̴ ȣÈí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, Àα¸ °í·ÉÈ­, Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó¿¡ ±âÀÎÇÕ´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á Á¢±Ù¼º °³¼±, ¿À¿°µµ Áõ°¡, Áß±¹ ¹× Àεµ¿Í °°Àº ±¹°¡¿¡¼­ È£Èí±â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â(Aerosol Drug Delivery Device) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, À¯Çüº°/¿ëµµº°/À¯Åë ä³Îº°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå Á¤ÀÇ¿Í Á¶»ç ÀüÁ¦

Á¦3Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â »ê¾÷ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Çüº°(2022³â-2032³â)

Á¦6Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°(2022³â-2032³â)

Á¦7Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°(2022³â-2032³â)

Á¦8Àå ¼¼°èÀÇ ¿¡¾î·ÎÁ¹ ¾à¹°Àü´Þ ±â±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022³â-2032³â)

Á¦9Àå °æÀï Á¤º¸

Á¦10Àå Á¶»ç °úÁ¤

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global aerosol drug delivery devices market was valued at USD 26.33 billion in 2023, with expectations to grow at a remarkable compound annual growth rate (CAGR) of 13.16% from 2024 to 2032. This growth is driven by the rising prevalence of respiratory diseases, the adoption of advanced inhaler technologies, and increasing healthcare awareness. The growing demand for home-based treatments further contributes to this growth, with inhalers and nebulizers becoming essential tools for managing chronic respiratory conditions such as asthma, COPD, and cystic fibrosis.

A key factor behind the market's growth is the increasing prevalence of respiratory diseases. According to the American Lung Association, over 11.7 million adults in the U.S. have been diagnosed with COPD. The World Health Organization (WHO) projects that by 2030, respiratory diseases will account for nearly one in five deaths worldwide. These statistics underscore the importance of aerosol drug delivery devices as critical solutions for disease management. Furthermore, the growing emphasis on healthcare access and innovation is contributing to the market's expansion.

Technological advancements in inhaler devices, particularly those that include sensors for usage tracking and improved adherence, are accelerating market growth. These innovations help patients manage their diseases more effectively, ensuring more precise delivery of medications. Additionally, as healthcare awareness continues to improve globally, especially in regions like Asia-Pacific, patients are increasingly opting for inhalers and nebulizers to manage their conditions more effectively.

The COVID-19 pandemic had a dual impact on the aerosol drug delivery devices market. It caused a surge in demand for these devices, as respiratory diseases like COVID-19 and its complications led to an increased need for respiratory support. However, the pandemic also led to disruptions in the global supply chain, affecting the production of these devices temporarily. Despite the challenges posed by the pandemic, the market is expected to continue its growth trajectory, driven by the rise in home healthcare services and the adoption of smart inhalation devices.

North America holds the largest share of the aerosol drug delivery devices market, accounting for more than 39% of the total revenue in 2024. This is due to the increasing incidence of respiratory diseases, an aging population, and a well-established healthcare infrastructure. However, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by improved healthcare access, rising pollution levels, and a growing awareness of respiratory diseases in countries like China and India.

Major market players included in this report are:

The detailed segments and sub-segments of the market are explained below:

By Type:

By Application:

By Distribution Channel:

By Region:

North America:

Europe:

Asia Pacific:

Latin America:

Middle East & Africa:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1. Global Aerosol Drug Delivery Devices Market Executive Summary

Chapter 2. Global Aerosol Drug Delivery Devices Market Definition and Research Assumptions

Chapter 3. Global Aerosol Drug Delivery Devices Market Dynamics

Chapter 4. Global Aerosol Drug Delivery Devices Industry Analysis

Chapter 5. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Type (2022 - 2032)

Chapter 6. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Application (2022 - 2032)

Chapter 7. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Distribution Channel (2022 - 2032)

Chapter 8. Global Aerosol Drug Delivery Devices Market Size & Forecasts by Region (2022 - 2032)

Chapter 9. Competitive Intelligence

Chapter 10. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â